Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
Priovant Therapeutics
生物技术研究
Durham，NC 2,791 位关注者
Developing targeted therapies for patients with severe autoimmune disease
关于我们
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens. We are rapidly developing a pipeline of medicines targeted to the specific molecular dysregulations underlying severe autoimmune conditions, unlocking new treatment options for patients who are underserved by existing therapies.
- 网站
-
https://priovanttx.com
Priovant Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Durham，NC
- 类型
- 私人持股
地点
-
主要
获取路线
US，NC，Durham
Priovant Therapeutics员工
-
Vandana Mathur, MD FASN
Clinical Drug Development and Strategy Consultant, Transplant Nephrologist and Clinical Trialist with broad range of experience including nephrology,…
-
Beth Anne Lang
Senior Vice President, Regulatory Affairs and Pharmacovigilance
-
Bruce Stevens
Senior Vice President, Quality
-
George Kokkines
General Counsel at Priovant Therapeutics
动态
-
Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
prnewswire.com
-
Excited to share our positive data for brepocitinib in non-infectious uveitis (NIU): https://lnkd.in/exqepsH3
Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
prnewswire.com